Biosimilars are copies of reference biological drugs, developed as the patents for original
biologicals expire. They are thus developed to replicate an original biological medicine just …

Patents for biologic agents first marketed in the 1980s are now beginning to expire, opening
the door for 'nonproprietary'versions of these agents to enter the market. However, there are …

One of the most crucial issues in pharmacotherapy is to address the query if a patient can be
switched from one product to another of the same active substance. For the conventional …

The use of biotech medicines is increasing, with consequent mounting expenses for
National Health Systems (NHSs). Biosimilars should be considered an opportunity to …

Biological therapies have transformed high-burden treatments. As the patent and exclusivity
period for biological medicines draws to a close, there is a possibility for the development …

The impending expiry of the patent on a number of leading biologic drugs has led to a surge
in the development of 'biosimilar'or 'follow-on'products. However, in contrast to generic small …

Biologic therapies have revolutionized treatment of a number of diseases. Patents and
exclusivity for a number of biologics are expiring. This has created the opportunity for the …

Importance of the field: Expiration of patents covering biopharmaceuticals, has provided
opportunities for pharmaceutical companies to develop, produce and market biosimilars or …

“Biologics”, considered one of the fastest growing sectors of the pharmaceutical industry,
has introduced many new treatments to life-threatening and rare illnesses. The first …

Patents for the first generation of approved biopharmaceuticals have either expired or are
about to expire. Thus the market is opening for generic versions, referred to as …